Masoabi Sefojane: In Africa 88% of Hemophilia Remains Undiagnosed
Masoabi Sefojane, Geographic Expansion Lead, Africa and Asia Pacific at MicroHealth , shared a post on LinkedIn:
”The World Federation of Haemophilia identifies 37% of people with haemophilia globally.
In low-income countries? 11%.
In Africa? An estimated 88% remain undiagnosed.
Let me be direct: these numbers represent invisibility by design.
Not because diagnosis is impossible.
But because the systems to find people were built for certain geographies and certain people.
When my brother was 6 years old in Phuthaditjhaba, South Africa, He didn’t exist in any global haemophilia dataset.
He was bleeding, my family was desperate, but he was invisible. No screening protocol would find him.
No registry would record him. No system knew he existed. This could have been my story if it wasn’t for my brothers.
Ask any bleeding disorder patient in the global south and you will hear similar stories and a pattern will also emerge.
Meanwhile, a child born with the same severe haemophilia A in Amsterdam? Known by age 1. Registered. Part of the data that shapes global priorities.
Same disease. Different visibility.
Here’s what the data shows: Africa, with 18% of the world’s population, represents less than 3% of identified haemophilia patients globally.
That’s not because haemophilia is rare in Africa. It’s because the systems designed to find haemophilia were never designed to reach Africa.
The invisibility isn’t accidental. It’s structural.
When a patient is invisible, they don’t exist in clinical trials. They’re not counted in epidemiology.
They don’t influence treatment guidelines. Their outcomes don’t matter because nobody’s measuring them.
The question we need to ask: Are we actually looking for these patients?
Or have we built systems that only find the ones in certain places?
Because that’s the real diagnosis gap.”

Stay updated with Hemostasis Today.
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics
-
Nov 14, 2026, 23:33Alexandros Makis: Exploring Vascular Mechanisms and Therapeutic Targets in β-Thalassemia